Abstract
Background: Diabetes is a complex chronic illness that adversely affects patients' quality of life. Approximately 425 million adults (20-79 years) were living with diabetes in 2017. Vitamin D levels had been shown to alter insulin synthesis and secretion suggesting its role in the pathogenesis of type 2 diabetes mellitus.
Aim of Study: To promote the quality of care provided to type 2 diabetic patients in the family practice setting.
Patients and Methods: This is a randomized controlled trial conducted on 60 uncontrolled type 2 diabetics. Patients were randomly allocated to Vitamin D3 group; received oral daily 2000IU of Cholecalciferol plus their usual care and a control group; received only their usual care for 3 months. Baseline anthropometrics, blood pressure, FBS, HBA1C, fasting insulin, HOMA indices and lipid profile were measured and repeated after 3 months.
Results: No statistically significant sociodemographic differences were found between both groups. The majority were younger than 60 years, hypertension was found in 76.7% of them. There were post intervention statistically significant differences (p<0.05) between both groups in blood pressure, FBS and HOMA-b. The pre-post relation in the intervention group shows statistically significant differences (p<0.05) in blood pressure, FBS, fasting insulin, HOMA-b  and HOMA-IR. There is a statistically significant positive correlation between HBA1C, blood pressure, and FBS.
Conclusion: Adding a daily dose of 2000IU of oral Vitamin D3 for type 2 diabetic patients may be beneficial through improving blood pressure, fasting blood glucose and HOMA-b.